Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.

Event:   H.C. Wainwright 24th Annual Global Investment Conference – September 12th-14th
Presentation:   Pre-recorded presentation available beginning September 12th at 7:00 AM (EDT)
Webcast link:   Here
1×1 Meetings:   Management will be available for one-on-one meetings during the conference, September 12th-14th

The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

Staff

Recent Posts

SI Group Awarded Bronze Medal by EcoVadis for Corporate Social Responsibility

Company Ranked in the Top 35% of All Rated Companies Underscoring the Company's Commitment to…

6 hours ago

S-E-A Expands Forensic Capabilities with High-Tech Industrial CT Scanner

COLUMBUS, Ohio, March 19, 2025 /PRNewswire/ -- Computed Tomography (CT) scanning, once primarily associated with medical…

6 hours ago

Tech Mahindra and NVIDIA Collaborate to Advance Drug Safety with Agentic AI-Powered Pharmacovigilance Solution

PUNE, India, March 19, 2025 /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading global provider…

6 hours ago

Stanford Medicine and LEADOPTIK Announce Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy

SAN JOSE, Calif., March 19, 2025 /PRNewswire/ -- LEADOPTIK Inc., a Silicon Valley-based medical imaging…

6 hours ago

NASDAQ-listed TNL Mediagene Provides AI-Powered CMS Technology to Japanese Publishers

NEW YORK and TOKYO, March 19, 2025 /PRNewswire/ -- Mediagene Inc., a group company of…

6 hours ago

Sisram Medical Announces 2024 Annual Results

New product launches drive double-digit growth in key markets and deliver market outperformance amid economic…

6 hours ago